9,763 reports of this reaction
2.8% of all USTEKINUMAB reports
#3 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #3 most commonly reported adverse reaction for USTEKINUMAB, manufactured by Janssen Biotech, Inc.. There are 9,763 FDA adverse event reports linking USTEKINUMAB to PRODUCT DOSE OMISSION ISSUE. This represents approximately 2.8% of all 346,490 adverse event reports for this drug.
USTEKINUMAB has an overall safety score of 78 out of 100. Patients taking USTEKINUMAB who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a less commonly reported adverse event for USTEKINUMAB, but still significant enough to appear in the safety profile.
In addition to product dose omission issue, the following adverse reactions have been reported for USTEKINUMAB:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 9,763 FDA reports for USTEKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 2.8% of all adverse event reports for USTEKINUMAB, making it one of the most commonly reported side effect.
If you experience product dose omission issue while taking USTEKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.